# Study of Dotatate Imaging in Breast Cancer

Source: https://onco.cc/trials/nct05880394/  
OnCo record `nct05880394` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Gallium-68 DOTATATE in Breast cancer, run by Hoag Memorial Hospital Presbyterian, with a status the registry has not verified recently.

## Summary

Study of Dotatate Imaging in Breast Cancer is a phase 2 interventional study registered as NCT05880394 by Hoag Memorial Hospital Presbyterian, with 30 participants planned, started 2023-01-10 and due to reach its primary completion in 2024-07-31. Interventions recorded: Gallium-68 DOTATATE, Copper-64 DOTATATE. Conditions recorded: Breast Cancer Stage IV.

Linked to the drug Gallium-68 DOTATATE because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05880394
- Phase: 2
- Setting: Somatostatin Receptor Imaging Study of Estrogen Receptor Positive (ER+) Metastatic Breast Cancer
- Sponsor: Hoag Memorial Hospital Presbyterian
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT05880394: https://clinicaltrials.gov/study/NCT05880394

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Gallium-68 DOTATATE (and Cu-64 DOTATATE)](https://onco.cc/drugs/ga68-dotatate/)

---
JSON: https://onco.cc/api/v1/entities/nct05880394.json